This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Hydrocortisone and crotamiton topical


Cream containing hydrocortisone and crotamiton

Drugs List

  • EURAX HC cream
  • hydrocortisone 0.25% and crotamiton 10% cream
  • Therapeutic Indications


    Skin disorder - mild inflammatory

    For the treatment of irritant contact dermatitis, allergic contact dermatitis, insect bite reactions and mild to moderate eczema.



    To be applied sparingly over a small area twice a day for a maximum period of 7 days.


    To be applied sparingly over a small area twice a day for a maximum period of 7 days.


    Children 10 to 18 years
    To be applied sparingly over a small area twice a day for a maximum period of 7 days.

    Children under 10 years
    Use only under medical supervision.


    Acute exudative dermatoses
    Perioral dermatitis
    Skin infection
    Skin ulcer

    Precautions and Warnings

    Children under 10 years

    Contains propylene glycol: may cause irritation
    Avoid contact with eyes
    Avoid contact with mucous membranes
    Avoid occlusive dressings
    Avoid prolonged application to the face
    Breastfeeding: Wash product off breasts prior to breastfeeding infant
    Do not apply to broken or denuded skin
    Do not apply to periorbital skin
    Do not apply to raw exudative dermatosis
    If accidental contact with eyes or mucous membranes - rinse with cool water
    Use sparingly
    Prolonged continuous use increases the risk of systemic toxicity
    Discontinue if irritation or sensitisation occur
    Maximum treatment 7 days unless on doctor's advice
    Advise patient residue on clothing/bedding may cause fire hazard
    Contact doctor if no improvement occurs
    Fire hazard: Keep away from naked flames and potential sources of ignition

    Pregnancy and Lactation


    Use topical hydrocortisone with crotamiton with caution in pregnancy.

    Schaefer concludes that there is no objection to topical therapy with glucocorticoids as long as treatment time is brief and the area covered is moderately sized. The manufacturer suggests use of topical hydrocortisone with crotamiton during pregnancy is not recommended, especially in the first three months.

    At the time of writing there is limited published information regarding the use of topical hydrocortisone with crotamiton during pregnancy. Less than 1% of crotamiton is absorbed after dermal application.

    Hydrocortisone crosses the human placenta to the foetus. Topical application of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intrauterine growth retardation. There may therefore be a very small risk of such effects in the human foetus but the relevance of this study has not been established in humans. Nevertheless, topical corticosteroids with the exception of very potent steroids can be used relatively safely in pregnancy.

    It is recommended to avoid using large amounts and for long periods of time if possible.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use topical hydrocortisone with crotamiton with caution in breastfeeding.

    The manufacturer suggests breastfeeding women should not use topical hydrocortisone with crotamiton unless under medical supervision.

    Corticosteroids generally appear only in low levels in human breast milk and the levels achieved from systemic absorption of topical applications are likely to be minimal. It is not known whether crotamiton or its metabolite(s) pass into the breast milk after topical administration.

    If applied to the breast area, the area should be washed and dried prior to breastfeeding and the preparation applied afterwards.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Contact dermatitis
    Hypersensitivity reactions
    Irritation (localised)
    Perioral dermatitis
    Skin atrophy
    Steroid acne


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2014

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Joint Formulary Committee. British National Formulary. 66th ed. London: BMJ Group and Pharmaceutical Press; 2013. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press [Accessed on January 07, 2014].

    Medications and Mothers' Milk, 14th Edition (2010) Hale, T. Hale Publishing, Amarillo, Texas.

    Paediatric Formulary Committee. BNF for Children 2013-2014. London: BMJ Group, Pharmaceutical Press, and RCPCH Publications; 2013. Paediatric Formulary Committee. BNF for Children (online) London: BMJ Group, Pharmaceutical Press, and RCPCH Publications [Accessed on January 07, 2014].

    Summary of Product Characteristics: Eurax Hc cream. Novartis Consumer Health. Revised December 2013.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Hydrocortisone, Topical. Last revised: January 16, 2014.
    Last accessed: January 21, 2014.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.